<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657448</url>
  </required_header>
  <id_info>
    <org_study_id>CYSEMS0112</org_study_id>
    <nct_id>NCT01657448</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of Dysuria</brief_title>
  <official_title>Phase III, Prospective, Multicenter, Single-blind, Randomized, Superiority to Evaluate the Efficacy and Safety of Methenamine Association 250mg + Methylthioninium Chloride 20 mg Compared to Phenazopyridine 100 mg in Symptomatic Control of Dysuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the combination of Methenamine +
      Methylthioninium chloride compared to phenazopyridine (comparator product) in the symptomatic
      relief of dysuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Single blind, randomized, prospective study.

        -  Length of experience: 03 days to 07 days.

        -  03 visits (days 1, 4 and 7).

        -  Evaluation of the efficacy and safety of the medication.

        -  Shall be assessed for adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of treatment in the symptomatic relief of dysuria</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the study medication</measure>
    <time_frame>7 days</time_frame>
    <description>To assess the safety of the study medication on the occurrence, type, intensity and frequency of adverse reactions during the treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Dysuria</condition>
  <arm_group>
    <arm_group_label>Methenamine, Methylthioninium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenazopyridine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methenamine and Methylthioninium chloride</intervention_name>
    <description>• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days</description>
    <arm_group_label>Methenamine, Methylthioninium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenazopyridine</intervention_name>
    <description>• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days</description>
    <arm_group_label>Phenazopyridine</arm_group_label>
    <other_name>Pyridium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who agree to participate by agreeing to the terms proposed in the Clinical
             trial;

          -  Patients aged over 18 years of any ethnicity;

          -  Presence of dysuria with marking greater than or equal to 5 measured points on the
             categorical scale pre-treatment for pain symptom;

        Exclusion Criteria:

          -  Patients who are febrile (axillary T º: ≥ 38 ° C), with back pain or lumbar;

          -  Patients with complicated clinical presentation of urinary tract infection;

          -  Patients with a history of allergy or intolerance to any known or suspected one of the
             ingredients of the product under investigation;

          -  Patients who are pregnant or during lactation, or childbearing potential and are not
             making use of effective contraception;

          -  Patients presenting with renal disease or severe liver disease, according to medical
             history and / or laboratory;

          -  Patients presenting with severe systemic disease according to the known medical
             history;

          -  Patients who received antibiotic treatment, anthelmintic within 7 days prior to study
             entry;

          -  Patients unable to understand the guidelines specified in this protocol or can not
             attend all study visits or unable to complete the log;

          -  Pregnancy or risk of pregnancy and lactating patients;

          -  Any finding of clinical observation (history and physical examination) that is
             interpreted by the physician investigator as a risk to the patient's participation in
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joyce Macedo Silva, MD</last_name>
    <phone>+ 55 19 9212 9851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Medicina Reprodutiva Carlos Isaia Filho Ltda</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Isaia Filho, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNISA</name>
      <address>
        <city>Santo Amaro</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Hime, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marcio Antonio Pereira Clinica de Endocrinologia</name>
      <address>
        <city>São José dos Campos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcio A. Pereira, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AFIP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helena H. Campos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Savmed Clinica Médica S/C Ltda.</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felício Savióli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedade de atendimento Cardiológico LTDA</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nabil Ghorayeb, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrícia Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ceci M Carvalho Lopes, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <last_update_submitted>August 24, 2015</last_update_submitted>
  <last_update_submitted_qc>August 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symptom of Dysuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methenamine</mesh_term>
    <mesh_term>Methenamine hippurate</mesh_term>
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

